Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Executive Summary

Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.


Related Content

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
Scangos Leaves Biogen Transformed And Transitioning
Novartis Rejiggers Pharma To Favor Oncology
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
Timeline At The Top: What Witty Did At GSK
Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
Despite CETP Loss, Lilly Says Long-Term Strategy Is Starting To Bear Fruit
Lilly CEO Lechleiter On Drug Pricing: ''The Facts Tell Us A Different Story''
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts